Literature DB >> 22803743

Humoral immunity to cytomegalovirus and chronic graft-versus-host disease.

Aryan M Namboodiri1, Paul J Nietert, Persis P Wadia, David B Miklos, Janardan P Pandey.   

Abstract

Human cytomegalovirus (HCMV) is an important cause of morbidity and mortality in patients with chronic graft-versus-host disease (cGVHD), but the underlying mechanisms are not understood. The aim of this investigation was to determine whether humoral immune responses to the HCMV antigens were quantitatively different in hematopoietic cell transplant (HCT) recipients who developed cGVHD from those who did not. Antibodies to HCMV and its proteins UL94 and UL70 were quantitated in 79 cGVHD and 30 non-cGVHD patients by enzyme-linked immunosorbent assays (ELISAs). Mean levels of antibodies to the whole HCMV and to its protein UL94 were not significantly different between the cGVHD and the non-cGVHD subjects. However, the levels of antibodies to HCMV UL70 were significantly higher in non-cGVHD subjects than in those with cGVHD (20.91±15.63 versus 15.00±10.35 ng/mL; p=0.03). This suggests that anti-UL70 antibodies might play a protective role in the development of cGVHD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22803743      PMCID: PMC3413074          DOI: 10.1089/vim.2012.0013

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  19 in total

Review 1.  Microchimerism and systemic sclerosis.

Authors:  C Scaletti; A Vultaggio; E Maggi; S Romagnani; M P Piccinni
Journal:  Int Arch Allergy Immunol       Date:  2001-07       Impact factor: 2.749

2.  A dual role for endothelial cells in cytomegalovirus infection? A study of cytomegalovirus infection in a series of rat endothelial cell lines.

Authors:  R C Vossen; J G Derhaag; M E Slobbe-van Drunen; A M Duijvestijn; M C van Dam-Mieras; C A Bruggeman
Journal:  Virus Res       Date:  1996-12       Impact factor: 3.303

3.  The effect of cytomegalovirus infection on the adherence of polymorphonuclear leucocytes to endothelial cells.

Authors:  A H Span; C P Van Boven; C A Bruggeman
Journal:  Eur J Clin Invest       Date:  1989-12       Impact factor: 4.686

4.  Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation.

Authors:  Yan Zhang; Laura L McCormick; Snehal R Desai; Caiyun Wu; Anita C Gilliam
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

5.  Effect of host genetics on the development of cytomegalovirus retinitis in patients with AIDS.

Authors:  Efe Sezgin; Douglas A Jabs; Sher L Hendrickson; Mark Van Natta; Alexander Zdanov; Richard Alan Lewis; Michael W Smith; Jennifer L Troyer; Stephen J O'Brien
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

6.  Cytomegalovirus-caused release of collagenase IV from human cerebral microvascular endothelial cells.

Authors:  S D Poland; G A Dekaban; P C Costello; G P Rice
Journal:  Clin Diagn Virol       Date:  1995-12

7.  Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells.

Authors:  C Lunardi; C Bason; R Navone; E Millo; G Damonte; R Corrocher; A Puccetti
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

Review 8.  HLA and autoimmunity in scleroderma (systemic sclerosis).

Authors:  F C Arnett
Journal:  Int Rev Immunol       Date:  1995       Impact factor: 5.311

9.  Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association.

Authors:  S A Bell; H Faust; J Mittermüller; H J Kolb; M Meurer
Journal:  Br J Dermatol       Date:  1996-05       Impact factor: 9.302

10.  Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes.

Authors:  T Muryoi; K N Kasturi; M J Kafina; D S Cram; L C Harrison; T Sasaki; C A Bona
Journal:  J Exp Med       Date:  1992-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.